Joinn Laboratories Forecasts Up to 1,377% Surge in H1 Profit

MT Newswires Live

Jul 14

Joinn Laboratories (SHA:603127, HKG:6127) expects an attributable profit of between 600.1 million yuan and 900.2 million yuan for the first half of 2026, up 885% to 1,377% from 60.9 million yuan a year prior.

Revenue is expected to increase 0% to 10.5% to between 668.6 million yuan and 739 million yuan from 668.6 million yuan in the year-ago period, according to a Tuesday Hong Kong bourse filing.

The drug research company attributed the profit forecast to a rise in the market price, and organic growth and appreciation of biological assets, leading to positive changes in their fair value, as well as stable operating status from the company's laboratories.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2651060681"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651060681\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651060681?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651060681","market":"us","top_or_hot":-1,"title":"Joinn Laboratories Forecasts Up to 1,377% Surge in H1 Profit","media":"MT Newswires Live","content":"<html><body><p> Joinn Laboratories (SHA:603127, HKG:6127) expects an attributable profit of between 600.1 million yuan and 900.2 million yuan for the first half of 2026, up 885% to 1,377% from 60.9 million yuan a year prior.</p><p>Revenue is expected to increase 0% to 10.5% to between 668.6 million yuan and 739 million yuan from 668.6 million yuan in the year-ago period, according to a Tuesday Hong Kong bourse filing.</p><p>The drug research company attributed the profit forecast to a rise in the market price, and organic growth and appreciation of biological assets, leading to positive changes in their fair value, as well as stable operating status from the company's laboratories.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Joinn Laboratories Forecasts Up to 1,377% Surge in H1 Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJoinn Laboratories Forecasts Up to 1,377% Surge in H1 Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-14 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Joinn Laboratories (SHA:603127, HKG:6127) expects an attributable profit of between 600.1 million yuan and 900.2 million yuan for the first half of 2026, up 885% to 1,377% from 60.9 million yuan a year prior.</p><p>Revenue is expected to increase 0% to 10.5% to between 668.6 million yuan and 739 million yuan from 668.6 million yuan in the year-ago period, according to a Tuesday Hong Kong bourse filing.</p><p>The drug research company attributed the profit forecast to a rise in the market price, and organic growth and appreciation of biological assets, leading to positive changes in their fair value, as well as stable operating status from the company's laboratories.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603127","symbol_name":"昭衍新药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651060681","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651060681","pubTimestamp":1784034849,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Joinn Laboratories  expects an attributable profit of between 600.1 million yuan and 900.2 million yuan for the first half of 2026, up 885% to 1,377% from 60.9 million yuan a year prior.Revenue is expected to increase 0% to 10.5% to between 668.6 million yuan and 739 million yuan from 668.6 million yuan in the year-ago period, according to a Tuesday Hong Kong bourse filing.The drug research company attributed the profit forecast to a rise in the market price, and organic growth and appreciation of biological assets, leading to positive changes in their fair value, as well as stable operating status from the company's laboratories.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603127":"昭衍新药","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK0216":"研究试验","06127":"昭衍新药","FCA":"First Trust China AlphaDEX Fund"},"translate_title":"Joinn Laboratories 预测上半年利润将激增高达 1,377%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603127":0.9,"06127":0.9,"FCA":0.9},"content_text":"Joinn Laboratories (SHA:603127, HKG:6127) expects an attributable profit of between 600.1 million yuan and 900.2 million yuan for the first half of 2026, up 885% to 1,377% from 60.9 million yuan a year prior.Revenue is expected to increase 0% to 10.5% to between 668.6 million yuan and 739 million yuan from 668.6 million yuan in the year-ago period, according to a Tuesday Hong Kong bourse filing.The drug research company attributed the profit forecast to a rise in the market price, and organic growth and appreciation of biological assets, leading to positive changes in their fair value, as well as stable operating status from the company's laboratories.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}